Scinai Reports Q1 Net Income of $3.6M from Non-Cash Gain; Operating Loss Widens to $2.5M Amid Cash Crunch
SCNI is trading near its 52-week low of $0.344 (8.2% below the low) on light trading volume (0.1× avg).
Summary
Scinai reported a Q1 2026 net income of $3.6 million, which was primarily driven by a $6.2 million non-cash bargain purchase gain from the Recipharm Israel acquisition. Excluding this one-time gain, the company's operating loss widened to $2.5 million, and revenues declined to $489,000. Cash and equivalents stood at a precarious $3.1 million as of March 31, 2026. This update follows the company's recent 20-F filing that cited critical going concern doubts and a Nasdaq delisting threat. While the expansion of the CDMO platform is a strategic move, the underlying operational performance and tight cash position remain significant concerns for the company's financial viability.
At the time of this announcement, SCNI was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.34 to $3.48. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.